Wells Fargo Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $18

Benzinga Newsdesk www.benzinga.com Positive 77.3%

Neg 0% Neu 0% Pos 77.3%

Wells Fargo analyst Yanan Zhu maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight and raises the price target from $14 to $18.